CA3034259A1 - Combination therapy for the treatment of pancreatic cancer - Google Patents

Combination therapy for the treatment of pancreatic cancer Download PDF

Info

Publication number
CA3034259A1
CA3034259A1 CA3034259A CA3034259A CA3034259A1 CA 3034259 A1 CA3034259 A1 CA 3034259A1 CA 3034259 A CA3034259 A CA 3034259A CA 3034259 A CA3034259 A CA 3034259A CA 3034259 A1 CA3034259 A1 CA 3034259A1
Authority
CA
Canada
Prior art keywords
pharmaceutically acceptable
acceptable salt
inhibitor
geneid
cobimetinib
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA3034259A
Other languages
English (en)
French (fr)
Inventor
Jeff SETTLEMAN
Nisebita SAHU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of CA3034259A1 publication Critical patent/CA3034259A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Enzymes And Modification Thereof (AREA)
CA3034259A 2016-08-23 2017-08-22 Combination therapy for the treatment of pancreatic cancer Abandoned CA3034259A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662378322P 2016-08-23 2016-08-23
US62/378,322 2016-08-23
PCT/US2017/047985 WO2018039211A1 (en) 2016-08-23 2017-08-22 Combination therapy for the treatment of pancreatic cancer

Publications (1)

Publication Number Publication Date
CA3034259A1 true CA3034259A1 (en) 2018-03-01

Family

ID=59762090

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3034259A Abandoned CA3034259A1 (en) 2016-08-23 2017-08-22 Combination therapy for the treatment of pancreatic cancer

Country Status (11)

Country Link
US (2) US10933058B2 (OSRAM)
EP (1) EP3503922B1 (OSRAM)
JP (2) JP7579636B2 (OSRAM)
KR (1) KR20190039951A (OSRAM)
CN (1) CN109641058A (OSRAM)
AU (1) AU2017316618A1 (OSRAM)
BR (1) BR112019002945A2 (OSRAM)
CA (1) CA3034259A1 (OSRAM)
IL (1) IL264589A (OSRAM)
MX (1) MX2019002121A (OSRAM)
WO (1) WO2018039211A1 (OSRAM)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7579636B2 (ja) * 2016-08-23 2024-11-08 ジェネンテック， インコーポレイテッド 膵がん治療のための組み合わせ治療薬
WO2020014650A1 (en) * 2018-07-13 2020-01-16 Memorial Sloan Kettering Cancer Center Methods of using pharmacologic inhibitors of type 2 cytokine signaling to treat or prevent pancreatic cancer
CA3186465A1 (en) * 2019-10-22 2021-04-29 Chemistry Rx Methods for treating congenital epidermal hyperplasia
US20230112450A1 (en) * 2020-03-06 2023-04-13 Beijing Sinotau Bio-Pharmaceuticals Technology Co., Ltd. Combined use of ctb006 and ponatinib
CN115813930A (zh) * 2021-08-17 2023-03-21 赛诺哈勃药业（成都）有限公司 大环化合物与mek抑制剂联用在用于治疗疾病药物中的用途
CN116509852A (zh) * 2023-04-30 2023-08-01 兰州大学第二医院 含zinc218238819化合物的胰腺癌jak2和stat3双靶向抑制剂及应用
CN116585312A (zh) * 2023-04-30 2023-08-15 兰州大学第二医院 含苯氧基丙酸化合物的胰腺癌jak2和stat3双靶向抑制剂及应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US9532987B2 (en) * 2013-09-05 2017-01-03 Genentech, Inc. Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases
EP3143166A4 (en) * 2014-05-16 2018-04-18 University of Massachusetts Treating chronic myelogenous leukemia (cml)
WO2016123054A2 (en) * 2015-01-26 2016-08-04 The University Of North Carolina At Chapel Hill Kinase drug combinations and methods of use thereof
EP3256473A4 (en) * 2015-02-12 2018-08-01 Memorial Sloan Kettering Cancer Center Synergistic cancer treatment
JP7579636B2 (ja) * 2016-08-23 2024-11-08 ジェネンテック， インコーポレイテッド 膵がん治療のための組み合わせ治療薬

Also Published As

Publication number Publication date
JP7579636B2 (ja) 2024-11-08
EP3503922B1 (en) 2022-10-26
MX2019002121A (es) 2019-08-12
US10933058B2 (en) 2021-03-02
JP2019526559A (ja) 2019-09-19
AU2017316618A1 (en) 2019-02-07
BR112019002945A2 (pt) 2019-05-21
WO2018039211A1 (en) 2018-03-01
KR20190039951A (ko) 2019-04-16
IL264589A (en) 2019-02-28
JP2024170398A (ja) 2024-12-10
US20190175576A1 (en) 2019-06-13
CN109641058A (zh) 2019-04-16
EP3503922A1 (en) 2019-07-03
US20210283120A1 (en) 2021-09-16
US12419879B2 (en) 2025-09-23

Similar Documents

Publication Publication Date Title
US12419879B2 (en) Combination therapy for the treatment of pancreatic cancer
ES3033810T3 (en) Cancer treatments using combinations of cdk and erk inhibitors
Yan et al. Aurora‐A kinase: a potent oncogene and target for cancer therapy
Saha et al. PRIMA-1Met/APR-246 displays high antitumor activity in multiple myeloma by induction of p73 and Noxa
US20200253979A1 (en) Therapeutic methods relating to hsp90 inhibitors
AU2014368916B2 (en) Cancer treatments using combinations of PI3K/Akt pathway and ERK inhibitors
US9408885B2 (en) Combinations of therapeutic agents for treating melanoma
Saiki et al. MDM2 antagonists synergize broadly and robustly with compounds targeting fundamental oncogenic signaling pathways
AU2016287507A1 (en) Methods of treating hematological malignancy using nanoparticle mTOR inhibitor combination therapy
RU2739992C2 (ru) Композиции апилимода и способы их применения в лечении колоректального рака
US20140348819A1 (en) Methods of Treating Cancer
Yang et al. Targeting RAS mutants in malignancies: successes, failures, and reasons for hope
WO2021262962A1 (en) Methods for treating cancer with combination therapies
Langdon et al. Combinatorial screening of pancreatic adenocarcinoma reveals sensitivity to drug combinations including bromodomain inhibitor plus neddylation inhibitor
Hou et al. Conquering oncogenic KRAS and its bypass mechanisms
WO2021099558A1 (en) Combination therapies
WO2021013794A1 (en) Transcriptomics for selecting druggable targets for combination therapy in cancer
Pan et al. STAT3 Inhibition Prevents Adaptive Resistance and Augments NK Cell Cytotoxicity to KRASG12C Inhibitors in Nonsmall Cell Lung Cancer
US20240398814A1 (en) Kras inhibitor and hdac inhibitor combination for the treatment of cancer
HK40001148A (en) Combination therapy for the treatment of pancreatic cancer
Dmello Discovering new treatments for colorectal cancer
CN115025229A (zh) 一种igf1r调控肿瘤干性因子cd44的新应用
Knickelbein Mechanisms and Novel Therapeutic Approaches for KRAS-Mediated Resistance to Anti-EGFR Therapy in Colorectal Cancer Cells
Langdon Combination high throughput compound screening for melanoma and lung adenocarcinoma
Lee et al. The Notch and b-Catenin Pathways

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20230223

FZDE Discontinued

Effective date: 20230223